Treating acute leukaemias of ambiguous lineage

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data

Five year update of ECHELON-1 for classical Hodgkin lymphoma

Off-the-shelf multi-virus specific T cells following haematopoietic stem cell transplantation

Blinatumomab and oral TKIs for the treatment of Ph ALL

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL

Real world management of multiple myeloma patients

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients